Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Products under Development by Stage of Development | 8 | 1 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Products under Development by Therapy Area | 9 | 1 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Products under Development by Indication | 10 | 2 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Unknown Stage Products | 14 | 1 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Products under Development by Companies | 15 | 3 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Therapeutics Assessment | 18 | 7 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Companies Involved in Therapeutics Development | 25 | 7 |
| BioLingus AG | 25 | 1 |
| Celsion Corporation | 26 | 1 |
| Clonz Biotech Private Limited | 27 | 1 |
| Epirus Biopharmaceuticals, Inc. | 28 | 1 |
| Johnson &Johnson | 29 | 1 |
| Oncobiologics, Inc. | 30 | 1 |
| OncoSec Medical Incorporated | 31 | 1 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Drug Profiles | 32 | 26 |
| DNA IL-12 Drug Profile | 32 | 9 |
| GEN-1 Drug Profile | 41 | 6 |
| Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis Drug Profile | 47 | 1 |
| ustekinumab Drug Profile | 48 | 6 |
| ustekinumab biosimilar Drug Profile | 54 | 1 |
| ustekinumab biosimilar Drug Profile | 55 | 1 |
| ustekinumab biosimilar Drug Profile | 56 | 1 |
| ustekinumab biosimilar Drug Profile | 57 | 1 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Dormant Projects | 58 | 1 |
| Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Featured News &Press Releases | 59 | 16 |
| Jun 16, 2016: OncoSec Presents Preliminary Findings from Head and Neck Phase II Clinical Trial at EUROGIN 2016 Conference | 59 | 1 |
| Jun 06, 2016: OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy | 60 | 1 |
| May 24, 2016: Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting | 60 | 2 |
| May 02, 2016: Celsion Announces Positive Data from the First Cohort of Patients in the OVATION Study | 62 | 1 |
| Apr 19, 2016: Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin and Doxil | 63 | 1 |
| Apr 19, 2016: OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research Annual Meeting 2016 | 64 | 1 |
| Apr 13, 2016: OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data | 65 | 1 |
| Apr 12, 2016: Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer | 66 | 1 |
| Mar 18, 2016: STELARA Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy | 66 | 2 |
| Mar 16, 2016: Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin and Doxil at the AACR Annual Meeting 2016 | 68 | 2 |
| Mar 02, 2016: OncoSec Completes Patient Enrollment in Phase II Extension Study of ImmunoPulse IL-12 in Melanoma | 70 | 1 |
| Feb 12, 2016: Celsion Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update | 70 | 2 |
| Jan 13, 2016: Health Canada Approves Stelara as First Biologic in North America For the Treatment of Moderate-to-Severe Psoriasis in Adolescents | 72 | 1 |
| Jan 07, 2016: Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer | 73 | 1 |
| Nov 30, 2015: Janssen Submits Applications Seeking Approval of Stelara in United States and European Union for Crohn's Disease | 74 | 1 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |